Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly Active Antibody-Dependent Cell Cytotoxicity.

Sojar H, Baron S, Sullivan JT, Garrett M, van Haaren MM, Hoffman J, Overbaugh J, Doranz BJ, Hicar MD.

J Virol. 2019 Aug 13;93(17). pii: e00772-19. doi: 10.1128/JVI.00772-19. Print 2019 Sep 1.

PMID:
31217246
2.

Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes.

Li L, Meng W, Horton M, DiStefano DR, Thoryk EA, Pfaff JM, Wang Q, Salazar GT, Barnes T, Doranz BJ, Bett AJ, Casimiro DR, Vora KA, An Z, Zhang N.

PLoS Pathog. 2019 Jun 6;15(6):e1007716. doi: 10.1371/journal.ppat.1007716. eCollection 2019 Jun.

3.

Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2.

Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE Jr, Bailey JR.

J Virol. 2019 Jun 28;93(14). pii: e02070-18. doi: 10.1128/JVI.02070-18. Print 2019 Jul 15.

PMID:
31068427
4.

Human antibody response to Zika targets type-specific quaternary structure epitopes.

Collins MH, Tu HA, Gimblet-Ochieng C, Liou GA, Jadi RS, Metz SW, Thomas A, McElvany BD, Davidson E, Doranz BJ, Reyes Y, Bowman NM, Becker-Dreps S, Bucardo F, Lazear HM, Diehl SA, de Silva AM.

JCI Insight. 2019 Apr 18;4(8). pii: 124588. doi: 10.1172/jci.insight.124588. eCollection 2019 Apr 18.

5.

Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.

Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, Diamond MS.

Sci Immunol. 2019 Feb 22;4(32). pii: eaav5062. doi: 10.1126/sciimmunol.aav5062.

PMID:
30796092
6.

Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.

Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr.

J Virol. 2019 Apr 3;93(8). pii: e01439-18. doi: 10.1128/JVI.01439-18. Print 2019 Apr 15.

PMID:
30728263
7.

Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.

Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, Bryan A, Davidson E, Doranz BJ, Kuhn RJ, Diamond MS, Crowe JE Jr, Rossmann MG.

Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1591-1596. doi: 10.1073/pnas.1815432116. Epub 2019 Jan 14.

8.

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.

Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.

PLoS One. 2018 Dec 19;13(12):e0209437. doi: 10.1371/journal.pone.0209437. eCollection 2018.

9.

Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection.

Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE Jr, Bjorkman PJ, Shaw GM, Bailey JR.

Cell Host Microbe. 2018 Nov 14;24(5):717-730.e5. doi: 10.1016/j.chom.2018.10.012.

PMID:
30439341
10.

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model.

Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB.

Cell Rep. 2018 Nov 13;25(7):1982-1993.e4. doi: 10.1016/j.celrep.2018.10.062.

11.

Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection.

Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium.

Cell. 2018 Aug 9;174(4):938-952.e13. doi: 10.1016/j.cell.2018.07.033.

12.

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.

Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE Jr.

Immunity. 2018 Aug 21;49(2):363-374.e10. doi: 10.1016/j.immuni.2018.06.018. Epub 2018 Jul 17.

13.

Mxra8 is a receptor for multiple arthritogenic alphaviruses.

Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, Lin H, Poddar S, Crowe JE Jr, Doranz BJ, Fremont DH, Diamond MS.

Nature. 2018 May;557(7706):570-574. doi: 10.1038/s41586-018-0121-3. Epub 2018 May 16.

14.

Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.

Tucker DF, Sullivan JT, Mattia KA, Fisher CR, Barnes T, Mabila MN, Wilf R, Sulli C, Pitts M, Payne RJ, Hall M, Huston-Paterson D, Deng X, Davidson E, Willis SH, Doranz BJ, Chambers R, Rucker JB.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E4990-E4999. doi: 10.1073/pnas.1716788115. Epub 2018 May 16.

15.

Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.

Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Nat Microbiol. 2018 Jun;3(6):670-677. doi: 10.1038/s41564-018-0157-z. Epub 2018 May 7.

16.

Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins.

Mousa JJ, Binshtein E, Human S, Fong RH, Alvarado G, Doranz BJ, Moore ML, Ohi MD, Crowe JE Jr.

PLoS Pathog. 2018 Feb 22;14(2):e1006837. doi: 10.1371/journal.ppat.1006837. eCollection 2018 Feb.

17.

Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.

Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, Pfaff JM, Barnes T, Honda A, Giang E, Davidson E, Wilson IA, Doranz BJ, Law M.

PLoS Pathog. 2017 Dec 18;13(12):e1006735. doi: 10.1371/journal.ppat.1006735. eCollection 2017 Dec.

18.

Enhancing antibody patent protection using epitope mapping information.

Deng X, Storz U, Doranz BJ.

MAbs. 2018 Feb/Mar;10(2):204-209. doi: 10.1080/19420862.2017.1402998. Epub 2017 Dec 7.

19.

High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.

Sullivan JT, Sulli C, Nilo A, Yasmeen A, Ozorowski G, Sanders RW, Ward AB, Klasse PJ, Moore JP, Doranz BJ.

J Virol. 2017 Oct 27;91(22). pii: e00862-17. doi: 10.1128/JVI.00862-17. Print 2017 Nov 15.

20.

The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket.

Thomas A, Sulli C, Davidson E, Berdougo E, Phillips M, Puffer BA, Paes C, Doranz BJ, Rucker JB.

Sci Rep. 2017 Aug 10;7(1):7753. doi: 10.1038/s41598-017-07256-y.

21.

Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ.

Cell. 2017 May 18;169(5):891-904.e15. doi: 10.1016/j.cell.2017.04.038.

22.

Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance.

Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, Ray SC, Crowe JE Jr.

JCI Insight. 2017 May 4;2(9). pii: 92872. doi: 10.1172/jci.insight.92872. eCollection 2017 May 4.

23.

Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.

Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ.

Cell Rep. 2017 Apr 11;19(2):413-424. doi: 10.1016/j.celrep.2017.03.049.

24.

A Biologically-validated HCV E1E2 Heterodimer Structural Model.

Castelli M, Clementi N, Pfaff J, Sautto GA, Diotti RA, Burioni R, Doranz BJ, Dal Peraro M, Clementi M, Mancini N.

Sci Rep. 2017 Mar 16;7(1):214. doi: 10.1038/s41598-017-00320-7.

25.

Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.

Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM.

J Virol. 2017 Feb 14;91(5). pii: e02041-16. doi: 10.1128/JVI.02041-16. Print 2017 Mar 1.

26.

Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.

Sapparapu G, Fernandez E, Kose N, Bin Cao, Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE.

Nature. 2016 Dec 15;540(7633):443-447. doi: 10.1038/nature20564. Epub 2016 Nov 7.

27.

Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.

Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE Jr.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6849-E6858. Epub 2016 Oct 17.

28.

Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.

Xu M, Züst R, Toh YX, Pfaff JM, Kahle KM, Davidson E, Doranz BJ, Velumani S, Tukijan F, Wang CI, Fink K.

J Virol. 2016 Nov 28;90(24):11122-11131. Print 2016 Dec 15.

29.

Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices.

Wescott MP, Kufareva I, Paes C, Goodman JR, Thaker Y, Puffer BA, Berdougo E, Rucker JB, Handel TM, Doranz BJ.

Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9928-33. doi: 10.1073/pnas.1601278113. Epub 2016 Aug 19.

30.

Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.

Hicar MD, Chen X, Sulli C, Barnes T, Goodman J, Sojar H, Briney B, Willis J, Chukwuma VU, Kalams SA, Doranz BJ, Spearman P, Crowe JE Jr.

PLoS One. 2016 Jul 13;11(7):e0158861. doi: 10.1371/journal.pone.0158861. eCollection 2016.

31.

Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.

Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ.

Cell Rep. 2016 May 17;15(7):1514-1526. doi: 10.1016/j.celrep.2016.04.026. Epub 2016 May 5.

32.

Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.

Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS.

J Virol. 2016 Apr 29;90(10):5090-5097. doi: 10.1128/JVI.00155-16. Print 2016 May 15.

33.

Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.

Godoy-Lozano EE, Téllez-Sosa J, Sánchez-González G, Sámano-Sánchez H, Aguilar-Salgado A, Salinas-Rodríguez A, Cortina-Ceballos B, Vivanco-Cid H, Hernández-Flores K, Pfaff JM, Kahle KM, Doranz BJ, Gómez-Barreto RE, Valdovinos-Torres H, López-Martínez I, Rodriguez MH, Martínez-Barnetche J.

Genome Med. 2016 Feb 25;8(1):23. doi: 10.1186/s13073-016-0276-1.

34.

Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.

Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr.

Cell. 2016 Jan 28;164(3):392-405. doi: 10.1016/j.cell.2015.12.022. Epub 2016 Jan 21.

35.

Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.

Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G.

Cell Rep. 2015 Dec 22;13(11):2553-2564. doi: 10.1016/j.celrep.2015.11.043. Epub 2015 Dec 10.

36.

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.

Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE Jr, Fremont DH, Rossmann MG, Diamond MS.

Cell. 2015 Nov 19;163(5):1095-1107. doi: 10.1016/j.cell.2015.10.050. Epub 2015 Nov 6.

37.

Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE Jr.

J Virol. 2015 Oct 28;90(2):780-9. doi: 10.1128/JVI.01805-15. Print 2016 Jan 15.

38.

Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity.

Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE Jr, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13898-903. doi: 10.1073/pnas.1515558112. Epub 2015 Oct 26.

39.

Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures.

Cox KS, Tang A, Chen Z, Horton MS, Yan H, Wang XM, Dubey SA, DiStefano DJ, Ettenger A, Fong RH, Doranz BJ, Casimiro DR, Vora KA.

MAbs. 2016;8(1):129-40. doi: 10.1080/19420862.2015.1109757. Epub 2015 Oct 22.

40.

Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.

Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ.

J Virol. 2015 Nov;89(21):10982-92. doi: 10.1128/JVI.01490-15. Epub 2015 Aug 26.

41.

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].

42.

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ.

J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.

43.

HCV E2 core structures and mAbs: something is still missing.

Castelli M, Clementi N, Sautto GA, Pfaff J, Kahle KM, Barnes T, Doranz BJ, Dal Peraro M, Clementi M, Burioni R, Mancini N.

Drug Discov Today. 2014 Dec;19(12):1964-70. doi: 10.1016/j.drudis.2014.08.011. Epub 2014 Aug 27. Review.

44.

A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes.

Davidson E, Doranz BJ.

Immunology. 2014 Sep;143(1):13-20. doi: 10.1111/imm.12323. Review.

45.

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44. doi: 10.1073/pnas.1317350111. Epub 2014 Jan 2. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115. Retraction in: Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2738.

46.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

47.

Atomic-level functional model of dengue virus Envelope protein infectivity.

Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18662-7. doi: 10.1073/pnas.1310962110. Epub 2013 Oct 24.

48.

A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.

Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G.

PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2423. doi: 10.1371/journal.pntd.0002423. eCollection 2013.

49.

Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors.

Sulli C, Banik SS, Schilling J, Moser A, Xiang X, Payne R, Wanless A, Willis SH, Paes C, Rucker JB, Doranz BJ.

J Virol. 2013 Oct;87(19):10679-86. doi: 10.1128/JVI.01190-13. Epub 2013 Jul 24.

50.

Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection.

Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2013 Aug;87(16):8826-42. doi: 10.1128/JVI.01314-13. Epub 2013 Jun 19.

Supplemental Content

Loading ...
Support Center